Gennex Laboratories Ltd

BSE: 531739

₹ 8.7-1.69%refreshed 23 Oct, 03:50 pm ISTMarket cap: ₹ 211 crWebsite: www.gennexlab.comUpdated: 24 Oct 2026

About

Gennex Laboratories makes bulk drugs (active pharmaceutical ingredients) and intermediates at manufacturing facilities in India, and sells them in India and abroad. It reports this as a single segment. Revenue was Rs 172.74 Cr in FY26.^[1][2]

Business and revenue by geography

The company reports one segment, Bulk Drugs & Intermediates, under Accounting Standard-17 (FY26).^[1]
Revenue by geography for that segment totalled Rs 119.86 Cr in FY26.^[1]
India: Rs 84.04 Cr of segment revenue in FY26 vs Rs 62.15 Cr in FY25.^[1][3]
Vietnam: Rs 13.47 Cr in FY26 vs Rs 10.93 Cr in FY25.^[1][3]
Colombia: Rs 8.54 Cr in FY26 vs Rs 4.93 Cr in FY25.^[1][3]
Egypt: Rs 3.8 Cr in FY26 vs Rs 5.2 Cr in FY25. Mexico: Rs 3.38 Cr in FY26 vs Rs 2.85 Cr in FY25.^[1][3]

Export markets

Other markets in FY26 included Bangkok, Guatemala, El Salvador, Ecuador, Russia, Germany and Spain.^[1]
In FY25, Peru brought in Rs 2.79 Cr and El Salvador Rs 2.52 Cr.^[3]
Foreign exchange earned was Rs 3036.94 lakhs in FY25 vs Rs 2111.26 lakhs the year before.^[3]

Regulatory approvals and certifications

The company received a COFEPRIS certificate from Mexico's national health regulator (FY26 annual report).^[1]
It holds GMP and WHO-GMP certification from the State Drug Licensing authority (FY26).^[1]
As of FY25 it held ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 certifications. It also held EU Written Confirmation for Guaifenesin, Methocarbamol and Phenazopyridine HCl.^[3]

Expansion and capex

Capital work-in-progress was Rs 5,31,59,615 as at 31 March 2026, up from Rs 2,62,41,812.^[1]
The company's investment in Deccan Remedies Limited is held for its expansion plans (FY26).^[1]

Group structure and ownership

As of FY26 the company held 6336165 equity shares in Deccan Remedies Limited, which the FY26 report describes as an associate. The FY25 report called it a 51% subsidiary.^[1][3]
Premier Fiscal Services (P) Ltd held 16.50% of the company's shares (FY26).^[1]

Funding

ICICI Bank sanctioned the company working capital limits of Rs 30 crores, secured by current assets (FY26).^[1]

Market Cap

₹211 Cr

High / Low

₹17 / 7

Stock P/E

11.9

Price / Book

1.0

Book Value

₹9

EPS

₹0.8

No. of Shares

24.29 Cr

ROCE

10.3%

ROE

9.0%

OPM

15.2%

Debt / Equity

0.16

Sales

₹173 Cr

Net Profit

₹21 Cr

Promoter holding

23.6%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

No earnings calls are on record for this company, so our models read its annual report and financials end-to-end - then value the business and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
P&L bridge from reported history - worst / average / best multiple cases.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials